GlassScriptPhysician profile
Robert A Innocenzi
NPI 1437172210
$5,156.34
in general payments reported to CMS, 2019-2025
26 companies · $893 in 2025
The $893 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $772 · 2020: $545 · 2021: $647 · 2022: $685 · 2023: $671 · 2024: $943 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,454 · Entertainment: $52.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,453.68 |
| Entertainment | $52.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,397.98 | 2019-2025 | Cequa |
| Allergan, INC. | $638.97 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $579.31 | 2023-2025 | Xiidra, Miebo, Envista Envy Iol |
| Alcon Vision LLC | $353.86 | 2019-2025 | Rocklatan, Tryptyr, Clareon |
| Aerie Pharmaceuticals, INC. | $296.84 | 2019-2021 | |
| Oyster Point Pharma, INC. | $218.31 | 2022-2024 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $180.71 | 2019-2022 | |
| Harrow Eye, LLC | $164.68 | 2024-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $150.83 | 2019-2022 | |
| Amgen INC. | $145.50 | 2025 | Tepezza |
| Dompe US, INC. | $127.68 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.30 | 2019-2020 | |
| Ivantis, INC | $101.25 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $100.67 | 2024-2025 | Xdemvy |
| Abbvie INC. | $90.89 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $85.74 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Johnson & Johnson Surgical Vision, INC. | $85.40 | 2022-2023 | Lipiflow System Activator (Disposable) |
| Kala Pharmaceuticals, INC. | $80.11 | 2020-2022 | |
| Shire North American Group INC | $67.19 | 2019 | |
| Optos, INC. | $52.74 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Thea Pharma INC. | $22.47 | 2023 | |
| Glaukos Corporation | $21.97 | 2021 | |
| Akorn, INC. | $20.13 | 2020 | |
| Horizon Therapeutics Plc | $19.40 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Lkc Technologies, INC. | $16.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Innocenzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.